Emerald Acquisition’s Aerie Pharmaceuticals AERI Stock Holding History

Emerald Acquisition’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$1.96M	Buy	+51,976	New	+$1.15M	﹤0.01%	1770

Other funds holding AERI

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Emerald Acquisition's AERI Position: Q3 2016 in Review

Emerald Acquisition opened a new position in Aerie Pharmaceuticals (AERI) in Q3 2016: 51,976 shares worth $1.96M. The stake represents ﹤0.01% of the portfolio and ranks #1770 among its holdings.

162 funds tracked by Wall St. Rank hold AERI as of Q3 2016.

Emerald Acquisition held 51,976 shares of Aerie Pharmaceuticals worth $1.96M as of Q3 2016.
Aerie Pharmaceuticals was a new Emerald Acquisition position in Q3 2016.
Aerie Pharmaceuticals made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #1770 holding.
162 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.